Herb–Drug Interactions: A Practical Guide for Herbalists

Herb–drug interactions occur when an herb changes how a medication is absorbed, transported, metabolized, eliminated, or expressed in the body. In some cases, an herb may lower a medication's concentration or effectiveness. In others, the combination may intensify a medication's effects or increase the likelihood of adverse reactions.

Not every proposed interaction becomes clinically meaningful. A laboratory finding, theoretical mechanism, isolated case report, and well-documented human interaction do not carry equal evidentiary weight. Responsible herbal practice requires more than collecting lists of herbs to avoid. It requires knowing how to identify a plausible concern, evaluate the available evidence, account for the exact preparation being used, and recognize when professional review is warranted.

The FDA advises people to disclose botanicals and dietary supplements alongside prescription and over-the-counter medicines because supplements can alter medication absorption, metabolism, or excretion.⁶ The agency also cautions that "natural" does not necessarily mean pharmacologically inactive or risk-free.

What Is an Herb–Drug Interaction?

An herb–drug interaction is a change in the activity, concentration, effectiveness, or adverse-effect profile of a medication associated with the use of an herb or botanical preparation.

The interaction may originate from the whole herb, a concentrated extract, one or more phytochemical constituents, or a product containing several ingredients. The medication involved may be prescription-only or available over the counter.

Several related concepts are often grouped together, but they are not identical:

Herb–drug interaction

An herb alters the pharmacokinetics or pharmacodynamics of a medication, or the medication changes the effects or processing of the herb.

Herb–herb interaction

Two botanical preparations produce complementary, opposing, or unexpectedly amplified effects when used together.

Contraindication

A circumstance in which a substance should generally not be used because the potential risk outweighs the anticipated benefit. A contraindication may involve a medication, medical condition, procedure, pregnancy, allergy, or another factor.

Adverse reaction

An unwanted response associated with an herb or medication. An adverse reaction can occur without another substance being present and therefore is not automatically an interaction.

Additive effect

An herb and medication influence the same physiological function in the same direction. The resulting effect may be intentional, neutral, or excessive depending on dose and clinical context.

Antagonistic effect

An herb and medication exert opposing effects, potentially reducing the intended effect of one or both substances.

The distinction matters. Labeling every adverse event an "interaction" makes the subject less precise. Conversely, focusing only on changes in blood concentration can overlook pharmacodynamic interactions that occur even when medication levels remain unchanged.

Pharmacokinetic vs. Pharmacodynamic Interactions

The two principal categories of herb–drug interaction are pharmacokinetic and pharmacodynamic.

Pharmacokinetic interactions

Pharmacokinetics describes what the body does to a substance.

A pharmacokinetic herb–drug interaction can change:

• How much medication is absorbed
• How quickly it enters circulation
• How it is transported across tissues
• How rapidly it is metabolized
• How long it remains active
• How it is eliminated

For example, an herb that induces a metabolic enzyme may increase the rate at which certain medications are processed. This can lower medication exposure and potentially reduce effectiveness. An herb that inhibits the same enzyme may slow metabolism and increase exposure, although the final result depends on the medication and whether it is administered in an active form or as a prodrug.

Cytochrome P450 enzymes and transport proteins such as P-glycoprotein are frequently discussed in the herb–drug interaction literature.¹² However, an effect observed in a test tube does not automatically mean that a typical human dose will produce the same effect in practice. Concentration, bioavailability, preparation, and duration all matter.

Pharmacodynamic interactions

Pharmacodynamics describes what a substance does to the body.

A pharmacodynamic interaction may occur when an herb and a medication both influence:

• Platelet activity or coagulation
• Blood pressure
• Blood glucose
• Sedation or alertness
• Serotonergic activity
• Immune activity
• Electrolyte balance
• Cardiac rhythm
• Liver or kidney stress

In these cases, medication concentrations may remain unchanged. The concern is that the herb and medication may produce additive, opposing, or otherwise altered physiological effects.

A simple example is a botanical preparation with antiplatelet activity used alongside a medication that also affects clotting. The combination may deserve additional scrutiny even when neither substance changes the other's metabolism.

The Principal Mechanisms Herbalists Should Recognize

An herbalist does not need to become a clinical pharmacologist to recognize the major interaction pathways. A working understanding of the following categories can substantially improve screening and documentation.

1. Enzyme induction

Enzyme induction increases the expression or activity of enzymes that process certain medications.

For many active medications, faster metabolism may lower circulating exposure and reduce therapeutic effect. Because enzyme induction can develop over repeated use and may take time to subside, simply taking the herb and medication at different times of day may not prevent the interaction.

St. John's wort (Hypericum perforatum) is the clearest botanical example. Research and regulatory guidance identify clinically important interactions involving induction of CYP3A4 and P-glycoprotein.²⁸ The degree of induction may also vary with the hyperforin content of the preparation.

2. Enzyme inhibition

Enzyme inhibition decreases the activity of an enzyme involved in medication metabolism.

For many active medications, slower metabolism may increase circulating exposure and the likelihood of concentration-dependent adverse effects. For prodrugs that require metabolic activation, inhibition may instead reduce formation of the active compound.

Goldenseal (Hydrastis canadensis) has demonstrated clinically relevant inhibition of CYP3A activity in human studies. In a clinical evaluation, goldenseal increased exposure to midazolam, a CYP3A probe drug, by approximately 40 to 60 percent.⁹

3. Drug-transporter effects

Transport proteins help move substances into or out of intestinal cells, the liver, kidneys, and other tissues.

An herb that inhibits or induces a transporter may alter absorption, distribution, or elimination. P-glycoprotein is one frequently studied example, but it is not the only transporter of potential relevance.

Transporter interactions are particularly complex because the same medication may be affected by more than one transporter and one metabolic enzyme. Laboratory evidence may also fail to predict the overall human effect.

4. Changes in absorption

Herbs may influence medication absorption through:

• Binding or adsorption
• Changes in gastrointestinal motility
• Changes in gastric emptying
• Alteration of intestinal transport
• Effects on acidity
• High fiber or mucilage content
• Changes in the intestinal environment

Some absorption-based interactions may be reduced through dose separation, but that strategy should not be generalized to metabolic, transporter-mediated, or pharmacodynamic interactions.

5. Additive physiological effects

An herb and medication may both lower blood pressure, increase sedation, affect glucose, influence clotting, or act on another shared physiological pathway.

An additive effect is not automatically harmful. Some combinations are used deliberately within coordinated care. The concern arises when the combined effect becomes excessive, unpredictable, or insufficiently monitored.

6. Antagonistic effects

An herb may oppose the intended action of a medication.

This can occur through a directly opposing physiological effect or through reduced medication exposure. In either case, the medication may appear less effective.

7. Effects involving a narrow therapeutic index

A medication has a narrow therapeutic index when the difference between an effective exposure and a potentially harmful or ineffective exposure is relatively small.

NCCIH advises particular care with medicines such as cyclosporine, digoxin, and warfarin because comparatively modest changes in exposure may have significant consequences.¹

Why Interaction Evidence Is Difficult to Interpret

The existence of a plausible mechanism is not the same as proof of a clinically meaningful interaction.

Herb–drug interaction claims may be supported by several kinds of evidence.

1. In-vitro studies — enzymes, transporters, cells, or tissues exposed to a substance under laboratory conditions; useful for identifying mechanisms, though the concentration used may be far higher than a person would reach.
2. Animal research — may provide mechanistic or safety signals, but species differences in metabolism, anatomy, dose scaling, and preparation limit direct application to humans.
3. Case reports — can flag an important signal, but frequently involve incomplete product information, multiple medications, uncertain adherence, or other possible explanations.
4. Human pharmacokinetic studies — measure whether an herb changes medication exposure in people; stronger evidence, though often small numbers of healthy volunteers, a single product, or a short exposure period.
5. Controlled clinical studies — may measure both pharmacokinetic changes and meaningful clinical outcomes; especially valuable but limited for many combinations.
6. Systematic reviews and established clinical evidence — can clarify consistency and quality across studies, though conclusions remain dependent on the underlying research.

Evidence strength also depends on whether the research matches the botanical species, plant part, preparation, dose, duration, medication, and population being evaluated. This represents a general progression of evidence, not an absolute scoring system.

The full picture requires reading each kind of evidence for what it can and cannot show:

In-vitro studies

These studies expose enzymes, transporters, cells, or tissues to a substance under laboratory conditions. They are useful for identifying possible mechanisms, but the concentration used may be far higher than a person would reach after taking a conventional preparation.

Animal studies

Animal studies may provide mechanistic or safety signals, but species differences in metabolism, anatomy, dose scaling, and preparation limit direct application to humans.

Case reports

A case report can identify an important signal, particularly when an unexpected event follows the addition or removal of an herb. However, case reports frequently involve incomplete product information, multiple medications, uncertain adherence, underlying illness, or other possible explanations.

Human pharmacokinetic studies

These studies measure whether an herb changes medication exposure in people. They can provide stronger evidence of a pharmacokinetic interaction, although studies may use small numbers of healthy volunteers, a single product, a probe dose, or a short exposure period.

Controlled clinical studies

Controlled trials may measure both pharmacokinetic changes and meaningful clinical outcomes. They are especially valuable but remain limited for many herb–medication combinations.

Systematic reviews

A well-conducted systematic review can clarify the consistency and quality of evidence across studies. Its conclusions remain dependent on the quality and comparability of the underlying research.

This distinction protects against two opposite errors:

1. Treating every laboratory finding as proof of a dangerous clinical interaction.
2. Dismissing a plausible interaction simply because large clinical trials have not been completed.

A responsible conclusion may be that an interaction is well established, probable, possible, theoretical, conflicting, or currently unknown.

Selected Herbs That Commonly Warrant Additional Review

The following examples are not a complete list of "dangerous herbs." They demonstrate why each botanical must be evaluated according to its preparation, mechanism, evidence, and clinical context.

St. John's wort

Hypericum perforatum

St. John's wort has one of the most clearly documented interaction profiles among commonly used herbal products.

It can induce CYP3A4 and P-glycoprotein, potentially reducing exposure to medications that depend on these pathways. NCCIH identifies interactions involving immunosuppressants, certain HIV and cancer medications, warfarin, some statins, digoxin, antiseizure medicines, and hormonal contraceptives.² It may also produce a pharmacodynamic interaction when combined with medications that increase serotonergic activity.

This is also an example of why the exact extract matters. Interaction potential may vary with hyperforin content, making the botanical name alone an incomplete description of the product.

Goldenseal

Hydrastis canadensis

Goldenseal has demonstrated effects on drug-metabolizing enzymes and intestinal transport processes.

Human research has shown inhibition of CYP3A activity.³⁹ A separate study in healthy volunteers found reduced exposure to a low dose of metformin when it was administered with goldenseal. More recent research in people with type 2 diabetes found no clinically meaningful aggregate change at therapeutic metformin doses, although the effect appeared to vary according to metformin dose.¹⁰

This evolving evidence is instructive. A measured pharmacokinetic change in healthy volunteers does not always translate directly into the same clinical effect in patients using therapeutic doses. At the same time, an aggregate result can obscure dose-dependent differences.

Ginkgo

Ginkgo biloba

Ginkgo is often discussed in relation to bleeding risk and medications that affect coagulation or platelet activity.

NCCIH advises that ginkgo may increase bleeding risk in people taking anticoagulants such as warfarin.⁴ However, the broader evidence is not uniform across every product, medication, and clinical setting.

The appropriate conclusion is not that every use of ginkgo inevitably causes bleeding. It is that anticoagulant or antiplatelet therapy, surgery, a history of abnormal bleeding, and use of additional products affecting hemostasis should lower the threshold for professional review.

Garlic supplements

Allium sativum

Garlic consumed as food should not automatically be treated as equivalent to a concentrated garlic supplement.

NCCIH notes that garlic supplements may increase bleeding risk and recommends disclosure before surgery or when medicines such as anticoagulants or aspirin are used.⁵ A review of supplements and bleeding also found an association between garlic supplementation and surgical bleeding.¹¹

This highlights the importance of documenting form and dose. Culinary exposure, powdered preparations, aged extracts, oils, and other concentrated products are not interchangeable.

A Six-Step Herb–Drug Interaction Assessment

The most useful interaction process is not memorizing a long blacklist. It is applying the same disciplined framework to every combination.

When Professional Review Is Especially Important

Certain circumstances deserve more caution even when the specific herb–drug interaction is not well documented. These include:

• Anticoagulant or antiplatelet therapy
• Immunosuppressive medication
• Antiseizure medication
• Sedatives or multiple central-nervous-system depressants
• Serotonergic medications
• Antiarrhythmic medication
• Cancer therapy
• Transplant medication
• Drugs requiring blood-level monitoring
• Planned surgery or anesthesia
• Multiple simultaneous medications
• Significant liver or kidney dysfunction
• Pregnancy or breastfeeding

The FDA notes that supplements may affect medications used before, during, or after surgery and may influence bleeding, blood pressure, or other perioperative factors.⁶⁷

Interaction Checkers and Reference Books: Strengths and Limitations

A good interaction reference can help a reader:

• Identify known and proposed interaction pathways
• Review contraindications and cautions
• Compare common and botanical names
• Recognize medications or medication classes requiring attention
• Locate relevant evidence more efficiently
• Ask better questions before combining products
• Document what was reviewed and when

But no book, database, or digital checker can independently determine whether a combination is appropriate for a specific person.

A reference cannot fully account for:

• The person's diagnoses
• Medication dose and blood concentration
• Liver and kidney function
• Genetics
• Age
• Pregnancy
• Product quality
• Adherence
• Several simultaneous interactions
• Changes in treatment
• The difference between a theoretical interaction and an immediate clinical problem

The correct role of an interaction reference is to support screening, research, documentation, and professional communication—not to replace clinical judgment.

A Better Documentation Habit for Herbalists

Interaction research becomes far more useful when the underlying details are recorded. Use the following checklist for each review:

Botanical information

• Common name
• Botanical name
• Plant part
• Product or manufacturer
• Preparation
• Extraction details
• Dose
• Frequency
• Duration
• Reason for use

Medication information

• Medication name
• Medication class
• Dose
• Frequency
• Relevant monitoring
• Prescribing clinician

Interaction assessment

• Proposed pharmacokinetic pathway
• Proposed pharmacodynamic pathway
• Evidence level
• Source reviewed
• Date reviewed
• Preparation studied
• Does the evidence match the current product?
• Potential consequence
• Professional consulted
• Decision or follow-up

This record prevents a broad database warning from being mistaken for a conclusion about a specific preparation and person.

Frequently Asked Questions

Conclusion

Herb–drug interaction assessment should not begin and end with a warning symbol.

A meaningful review identifies the exact herb and preparation, examines both pharmacokinetic and pharmacodynamic pathways, grades the quality of the evidence, considers the medication's risk profile, and documents the reasoning behind the final decision.

Some interactions—particularly those involving St. John's wort—are supported by substantial human and clinical evidence. Others remain theoretical, product-dependent, dose-dependent, conflicting, or insufficiently studied. Treating all of them as equally certain creates unnecessary fear. Treating uncertainty as proof of safety creates a different and potentially more serious problem.

Responsible herbal practice occupies the ground between those extremes. It asks:

• What exactly is being used?
• What mechanism is proposed?
• What kind of evidence supports it?
• Does that evidence apply to this preparation and medication?
• What would be the consequence if the assessment were wrong?
• Who should be involved before proceeding?

That process does more than help avoid adverse combinations. It creates a more informed, transparent, and professionally credible approach to herbal decision-making.